Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 8/20 | 0.40 |
| ▸ | HTR6 | P50406 | 6/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205868 | 0.83 | AKT1 (0.37) | HTR6PDE4ACHRM5CHRM1 | |
| SCHEMBL3215142 | 0.83 | HTR6 (0.39) | KDM2BHTR6CXCR4CHRM5CHRM2 | |
| SCHEMBL3214560 | 0.83 | HTR6 (0.50) | HTR6DRD2DRD3 | |
| SCHEMBL3223782 | 0.81 | HTR6 (0.47) | KDM2BHTR6DRD2 | |
| SCHEMBL7947328 | 0.81 | MET (0.45) | KDM2BHTR6CXCR4CHRM5CHRM2 | |
| SCHEMBL3220703 | 0.81 | HTR6 (0.44) | KDM2BHTR6 | |
| SCHEMBL3624804 | 0.81 | HTR6 (0.43) | HTR6DRD2 | |
| SCHEMBL3215703 | 0.80 | HTR6 (0.54) | HTR6DRD2DRD3 | |
| SCHEMBL3221961 | 0.80 | HTR6 (0.45) | KDM2BHTR6CHRM2CHRM1 | |
| SCHEMBL3222864 | 0.79 | MET (0.48) | KDM2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | claimed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010020548-A1 | GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021797-A1 | CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021797-A1 | CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | KDM2B 2736/4885HTR6 1/4885PDE4A 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.